Leerink Partners on Insmed (INSM): competitor data gives positive readthrough, continues re-rate
Tweet Send to a Friend
Leerink Partners analyst Joseph P. Schwartz reiterated an Outperform rating and $215.00 price target on Insmed (NASDAQ: INSM)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
